Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement

類似資料

• Induced Resistance to Ofatumumab Mediated Cell Clearance Mechanisms, Including Complement Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia
  著者:: Baig, Nisar A., 等
  出版事項: (2014)
• Direct and Complement Dependent Cytotoxicity in CLL Cells from Patients with High Risk Early Stage Chronic Lymphocytic Leukemia (CLL) Treated with Alemtuzumab and Rituximab
  著者:: Zent, Clive S., 等
  出版事項: (2008)
• Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated CLL
  著者:: Shanafelt, Tait, 等
  出版事項: (2013)
• Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab is Effective and Tolerable and Limits Loss of CD20 Expression by Circulating CLL Cells
  著者:: Zent, Clive S., 等
  出版事項: (2014)
• The Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) with Everolimus Results in Clinical Responses and Mobilization of CLL Cells into the Circulation
  著者:: Zent, Clive S., 等
  出版事項: (2010)